RxDoctor Payments Data

John Wolcott, MD

Family Medicine · Kilgore, TXNPI 1396740064

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 172 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$411
  • Merck$354
  • Novo Nordisk$293
  • AstraZeneca$259
  • GSK$223
  • Amgen$198
  • plus $845 from 13 others

What the payments were for

  • Food & beverage$2,56399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,582 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$45,358
Medicare patients
135
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$128,297
MounjaroTirzepatide90$110,440
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$60,233
JardianceEmpagliflozin64$52,858
EliquisApixaban75$45,792
TrulicityDulaglutide26$38,118
FarxigaDapagliflozin Propanediol26$24,184
GlyxambiEmpagliflozin/Linagliptin31$23,621
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$21,143
RybelsusSemaglutide12$20,376
Tresiba Flextouch U-200Insulin Degludec13$15,286
BelsomraSuvorexant30$13,815
Breo ElliptaFluticasone/Vilanterol22$13,190
LinzessLinaclotide17$13,059
KerendiaFinerenone17$10,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$293$148,672114 claims
Lilly USA, LLCMounjaro, Trulicity$188$148,558116 claims
GSKTrelegy Ellipta, Breo Ellipta$223$73,42388 claims
PfizerEliquis$94$45,79275 claims
AstraZenecaFarxiga, Symbicort$259$29,95841 claims
MerckBelsomra, Januvia$354$22,31147 claims
AbbVieLinzess$85$13,05917 claims
BayerKerendia$411$10,87417 claims
Astellas Pharma US IncMyrbetriq$17$7,21116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Kilgore

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →